A computer-generated receptor-binding prediction can identify an idea to test. It cannot, by itself, show that a compound blocks methamphetamine’s effects or treats dependence. That distinction is central to reading a 2025 study by Ridgway and colleagues on simulated interactions involving angiotensin, adrenergic and opioid receptors.
The paper includes methamphetamine among adrenergic-receptor comparator ligands and discusses possible applications of sartans and experimental bisartans to methamphetamine addiction. Its results require a careful separation of computational observations from hypotheses about biological and clinical effects.
What kind of study was this?
The new analyses were molecular docking and molecular dynamics simulations. The investigators used receptor structures and modeled how selected molecules could fit into receptor-binding regions. This is in silico evidence, rather than a trial in people with methamphetamine dependence.
The paper also discusses earlier tissue and animal experiments, including vascular responses to other agonists. Those cited experiments do not turn each new computer prediction into an independently verified biological finding. An effect on phenylephrine-induced contraction, for example, is not the same experiment as treating methamphetamine dependence.
Where did methamphetamine enter the comparison?
In discussing global docking at alpha-adrenergic receptors, the authors reported stronger predicted binding for selected sartans and bisartans than for several comparator ligands, including methamphetamine. They explicitly acknowledged that an unexpected ranking might reflect computational bias or binding that does not produce biological activity.
This was a comparison of modeled receptor interactions. It did not measure methamphetamine concentrations in blood or brain, displacement in a living person, reversal of an intoxication endpoint, or a change in drug consumption.
A molecule receiving a stronger docking score than methamphetamine therefore should not be described as experimentally demonstrated to overpower methamphetamine in the body.
What did the reported numbers represent?
The docking method used AutoDock VINA through the YASARA modeling environment. Binding-site searches used the best result from at least 500 runs per ligand. Global searches began with randomized ligand placement and conformation and used at least 900 runs per ligand.
These are computational search runs, not numbers of animals, patients or independent clinical replications. Repeating a search can help find favorable configurations within a model, but does not supply biological observations missing from that model.
The paper reported binding-energy scores in kcal/mol using a positive-value convention, with more positive values designated as stronger binding. It also expressed calculated dissociation constants on a logarithmic picomolar scale. Neither quantity is a measured human drug concentration or a clinical dose.
Does predicted binding identify activation or blockade?
No functional response was established merely by assigning a favorable pose and score. A prediction that a ligand can occupy a modeled region does not independently determine whether it activates signaling, blocks an agonist, produces a partial effect, or has little functional consequence.
The paper itself discusses discrepancies between docking rankings and biological potency. It proposes explanations involving receptor state, signaling partners and possible software bias. Those competing explanations are a reason to retain uncertainty, rather than to select whichever interpretation best supports a therapeutic claim.
For the methamphetamine comparison, the missing step is especially consequential: a predicted interaction with an adrenergic receptor does not establish a beneficial effect on the behaviors or clinical outcomes relevant to dependence.
Did molecular dynamics validate the methamphetamine result?
The investigators followed selected docking results with molecular dynamics simulations, examining the experimental bisartan ACC519TT in selected receptor complexes over approximately 150–200 nanoseconds. The ligand generally remained within the modeled binding regions.
That result concerns stability of selected simulated complexes over a very short modeled interval. It is not a direct validation of every ligand-receptor ranking, and it should not be relabeled as a methamphetamine treatment experiment.
The authors also acknowledged that some receptor conformational changes could reflect early relaxation of the modeled complexes rather than an established transition between functional receptor states. A plausible trajectory does not resolve every ambiguity in the underlying receptor model.
Why is the dependence hypothesis a further step?
The discussion proposes connections between receptor desensitization, tolerance and addiction, and suggests investigating whether modifying receptor sensitivity could have therapeutic value. Those proposals extend beyond the measured computational endpoints.
The study did not operationally test drug taking, withdrawal, relapse or a clinical diagnosis in the simulated systems. It therefore cannot establish that these outcomes are interchangeable consequences of the same modeled receptor state. Nor can a docking score demonstrate that changing that state would improve a person’s condition.
Such a treatment claim would require biological evidence of the relevant action, evidence that the compound reaches the necessary site at a usable exposure, and studies measuring the claimed clinical outcome. The docking comparison supplies none of those steps on its own.
What is the defensible use of this paper?
The study can be used to identify proposed receptor interactions and experiments that might test them. Its authors explicitly describe hypothetical and speculative elements, and recognize that apparent binding does not necessarily produce a response.
For an evidence review, the practical questions are whether a quoted number was measured or computed, which ligand was actually simulated, whether functional activity was tested, and whether the cited outcome involved methamphetamine at all. Keeping those questions attached to the result preserves the difference between a research lead and an established treatment.
References
Ridgway H, Moore GJ, Gadanec LK, Matsoukas JM. Docking simulations of G-protein coupled receptors uncover crossover binding patterns of diverse ligands to angiotensin, alpha-adrenergic and opioid receptors: implications for cardiovascular disease and addiction. Biomolecules. 2025;15(6):855. doi:10.3390/biom15060855. Primary computational research; proposed clinical implications require separate validation.
Leave a Reply